In addition, the results in Figure 7 indicate that the treatment of ALL by MSMY may be mainly related to the cancer pathway, phosphatidylinositol 3 kinase, PI-3K/protein kinase B (PI3K-Akt) signaling pathway, apoptosis and mitogen-activated protein kinase (MAPK) signaling pathway, and IL-17 signaling pathway. The gene discussed is IL17A; the disease is acute lymphoblastic leukemia.